ImmuCell Q3 2023 Gaap EPS $(0.12) Down From $(0.08) YoY, Sales $5.40M Up From $4.80M YoY
Portfolio Pulse from saritha@benzinga.com
ImmuCell Corporation reported a Q3 2023 GAAP EPS loss of $(0.12), which is a 50% increase in losses compared to $(0.08) per share in the same quarter last year. However, sales rose to $5.40M, marking a 12.53% increase from $4.80M in the same period last year.
November 13, 2023 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ImmuCell's Q3 2023 results indicate a widening loss per share but also an increase in sales compared to the previous year.
The increased loss per share could concern investors about profitability, potentially putting downward pressure on the stock price. However, the rise in sales suggests growth, which could counterbalance the negative impact on the stock. The mixed results lead to a neutral short-term impact score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100